- Home
- LYEL vs DRDB Comparison
LYEL vs DRDB Comparison
Compare LYEL & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | DRDB |
|---|---|---|
| Founded | 2018 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.1M | 326.9M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LYEL | DRDB |
|---|---|---|
| Price | $10.42 | $10.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.60 | N/A |
| AVG Volume (30 Days) | ★ 94.5K | 12.5K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8,712.13 | N/A |
| P/E Ratio | ★ N/A | $597.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.46 | $10.30 |
| 52 Week High | $45.00 | $10.69 |
Technical Indicators
Market Signals| Indicator | LYEL | DRDB |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 64.37 |
| Support Level | $10.46 | $10.42 |
| Resistance Level | $15.38 | N/A |
| Average True Range (ATR) | 0.70 | 0.01 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 11.86 | 85.72 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.